Stephen J. Noga

3.7k total citations · 1 hit paper
82 papers, 2.4k citations indexed

About

Stephen J. Noga is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Stephen J. Noga has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 34 papers in Oncology and 32 papers in Molecular Biology. Recurrent topics in Stephen J. Noga's work include Multiple Myeloma Research and Treatments (34 papers), Protein Degradation and Inhibitors (22 papers) and Hematopoietic Stem Cell Transplantation (18 papers). Stephen J. Noga is often cited by papers focused on Multiple Myeloma Research and Treatments (34 papers), Protein Degradation and Inhibitors (22 papers) and Hematopoietic Stem Cell Transplantation (18 papers). Stephen J. Noga collaborates with scholars based in United States, South Africa and Japan. Stephen J. Noga's co-authors include Ian W. Flinn, Tarun Kewalramani, John M. McCarty, Christos Emmanouilides, Patrick J. Stiff, Thomas C. Shea, Eric Sung, Bruce R. Blazar, D. Elhardt and C. Frederick LeMaistre and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen J. Noga

80 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers

2004 606 citations Stephen J. Noga et al. profile →

Peers

Stephen J. Noga

HEMAT

ONCOL

PRM

IMMUN

Dusan Kotasek Australia

A. Thyss France

Ye Guo China

E. Fritz Austria

Uğur Çoşkun Türkiye

Josef Thaler Austria

Dolors Tàssies Spain

Giuseppina Catalano Italy

Ann B. Zimrin United States

Fadi Haddad United States

Dusan Kotasek Australia

Stephen J. Noga

577 ×0.5

HEMAT

1.2k ×1.1

ONCOL

448 ×0.6

542 ×1.0

PRM

227 ×0.8

IMMUN

Citations per year, relative to Stephen J. Noga Stephen J. Noga (= 1×) peers Dusan Kotasek

Countries citing papers authored by Stephen J. Noga

Since Specialization

Citations

This map shows the geographic impact of Stephen J. Noga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Noga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Noga more than expected).

Fields of papers citing papers by Stephen J. Noga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Noga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Noga. The network helps show where Stephen J. Noga may publish in the future.

Co-authorship network of co-authors of Stephen J. Noga

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen J. Noga. A scholar is included among the top collaborators of Stephen J. Noga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen J. Noga. Stephen J. Noga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nooka, Ajay K., Nisha S. Joseph, Vikas A. Gupta, et al.. (2023). A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood. 142(Supplement 1). 4764–4764. 1 indexed citations

Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations

Rifkin, Robert M., Ralph V. Boccia, Suman Kambhampati, et al.. (2017). Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen. Blood. 130. 5407–5407. 3 indexed citations

Yong, Candice, et al.. (2017). Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy. Blood. 130. 3423–3423. 1 indexed citations

Berenson, James R., James Hilger, Ori Yellin, et al.. (2013). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology. 93(1). 89–98. 34 indexed citations

Guo, Ying, Desirée Jones, J. Lynn Palmer, et al.. (2013). Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Supportive Care in Cancer. 22(5). 1223–1231. 83 indexed citations

Sierra, Jorge, Jeff Szer, Jeannine Kassis, et al.. (2008). A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 8(1). 195–195. 40 indexed citations

Noga, Stephen J., J. K. Choksi, Beiying Ding, Lyndah Dreiling, & Howard Ozer. (2007). Low Incidence of Neutropenic Events in Patients with Lymphoma Receiving First-Cycle Pegfilgrastim with Chemotherapy: Results from a Prospective Community-Based Study. Clinical Lymphoma & Myeloma. 7(6). 413–420. 8 indexed citations

Rouard, Hélène, A. Léon, Jeanine Marquet, et al.. (2003). A closed and single‐use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion. 43(4). 481–487. 23 indexed citations

10.

Huff, Carol Ann, Ephraim J. Fuchs, Stephen J. Noga, et al.. (2003). Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biology of Blood and Marrow Transplantation. 9(5). 312–319. 25 indexed citations

11.

Wall, Elsken van der, Thomas Horn, Emilie C. Bright, et al.. (2000). Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. British Journal of Cancer. 83(11). 1405–1411. 13 indexed citations

12.

Gladstone, Douglas E., Atul Bedi, Carole B. Miller, et al.. (1999). Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation. 5(6). 394–399. 11 indexed citations

13.

Jeong, Dae Chul, Chi Wha Han, Jong‐Youl Jin, et al.. (1999). Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Experimental Hematology. 27(7). 1219–1225. 3 indexed citations

14.

Noga, Stephen J., Adriana Seber, Janice M. Davis, et al.. (1998). CD34 Augmentation Improves Allogeneic T Cell-Depleted Bone Marrow Engraftment. Journal of Hematotherapy. 7(2). 151–157. 16 indexed citations

15.

Passos‐Coelho, José Luís, John M. Davis, A M Huelskamp, et al.. (1996). Comparative Analysis of Breast Cancer Contamination in Mobilized and Nonmobilized Hematopoietic Grafts. Journal of Hematotherapy. 5(5). 549–552. 11 indexed citations

16.

Civin, Curt I., Thomas M. Trischmann, Nina S. Kadan‐Lottick, et al.. (1996). Highly purified CD34-positive cells reconstitute hematopoiesis.. Journal of Clinical Oncology. 14(8). 2224–2233. 116 indexed citations

17.

Passos‐Coelho, José Luís, H. Braine, Susan Wright, et al.. (1995). Large-Volume Leukapheresis Using Regional Citrate Anticoagulation to Collect Peripheral Blood Progenitor Cells. Journal of Hematotherapy. 4(1). 11–19. 43 indexed citations

18.

Davis, Janice M., et al.. (1993). Comparison of Progenitor Cell Concentration Techniques: Continuous Flow Separation versus Density-Gradient Isolation. Journal of Hematotherapy. 2(3). 315–320. 9 indexed citations

19.

Noga, Stephen J., et al.. (1992). Interferon-γ Potentiates the Antitumor Effect of Cyclosporine-Induced Autoimmunity. Journal of Hematotherapy. 1(1). 75–84. 27 indexed citations

20.

Hess, Allan D., Richard J. Jones, Lawrence E. Morris, et al.. (1992). Autologous graft-versus-host disease: A novel approach for antitumor immunotherapy. Human Immunology. 34(3). 219–224. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact